Towards 50 years of platelet function analyser (PFA) testing.
PFA-100
PFA-200
in vitro bleeding time
platelet function analyser
Journal
Clinical chemistry and laboratory medicine
ISSN: 1437-4331
Titre abrégé: Clin Chem Lab Med
Pays: Germany
ID NLM: 9806306
Informations de publication
Date de publication:
25 04 2023
25 04 2023
Historique:
received:
10
07
2022
accepted:
11
07
2022
medline:
3
4
2023
pubmed:
21
7
2022
entrez:
20
7
2022
Statut:
epublish
Résumé
The platelet function analyser (PFA) is a prevalent platelet function screening instrument, and comes in two models-the original PFA-100 and the contemporary PFA-200. The instruments have 'identical' output, being a 'closure time' (CT). Moreover, normal reference ranges provided by the manufacturer, for the specific test cartridges, are the same for both models. There are three different types of test cartridge: collagen/epinephrine (C/Epi), collagen/adenosine diphosphate (C/ADP), and "Innovance PFA P2Y" (only available in certain geographical locations). The PFA-100 was released in the mid 1990s, and so is approaching 50 years of age. The PFA-200, released in some locations in the mid 2010s, is destined to eventually replace the PFA-100, but is not yet available in the USA. The test system is highly sensitive to von Willebrand disease (VWD; C/Epi and C/ADP) and to aspirin therapy (C/Epi only), but only has moderate sensitivity to defects in platelet function and/or deficiencies in platelet number. Accordingly, recommendations for use for screening platelet function vary according to user experience. Some workers have alternatively used the PFA to assess thrombosis risk or pre-operative bleeding risk. In this review, we provide an overview of the history of PFA, and summarise its current clinical utility.
Identifiants
pubmed: 35859143
pii: cclm-2022-0666
doi: 10.1515/cclm-2022-0666
doi:
Substances chimiques
Epinephrine
YKH834O4BH
Adenosine Diphosphate
61D2G4IYVH
Collagen
9007-34-5
Types de publication
Review
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
851-860Informations de copyright
© 2022 Walter de Gruyter GmbH, Berlin/Boston.
Références
Kundu, S, Sio, R, Mitu, A, Ostgaard, R. Evaluation of platelet function by PFA-100. Clin Chem 1994;40:1827–8. https://doi.org/10.1093/clinchem/40.9.1827 .
doi: 10.1093/clinchem/40.9.1827
Kundu, SK, Heilmann, EJ, Sio, R, Garcia, C, Davidson, RM, Ostgaard, RA. Description of an in vitro platelet function analyzer--PFA-100. Semin Thromb Hemost 1995;21:106–12. https://doi.org/10.1055/s-0032-1313612 .
doi: 10.1055/s-0032-1313612
Mammen, EF, Alshameeri, RS, Comp, PC. Preliminary data from a field trial of the PFA-100 system. Semin Thromb Hemost 1995;21:113–21. https://doi.org/10.1055/s-0032-1313613 .
doi: 10.1055/s-0032-1313613
Van der Planken, MG, Claeys, MJ, Vertessen, FJ, Dilling, D, Bosmans, JM, Berneman, ZN, et al.. Comparison of turbidimetric aggregation and in vitro bleeding time (PFA-100) for monitoring the platelet inhibitory profile of antiplatelet agents in patients undergoing stent implantation. Thromb Res 2003;111:159–64. https://doi.org/10.1016/j.thromres.2003.09.002 .
doi: 10.1016/j.thromres.2003.09.002
Troost, MM, van Genderen, PJ. Excessive prolongation of the Ivy bleeding time after aspirin in essential thrombocythemia is also demonstrable in vitro in the high shear stress system PFA-100. Ann Hematol 2002;81:353–4. https://doi.org/10.1007/s00277-002-0462-7 .
doi: 10.1007/s00277-002-0462-7
Sap, F, Kavaklı, T, Kavaklı, K, Dizdarer, C. The prevalence of von Willebrand disease and significance of in vitro bleeding time (PFA-100) in von Willebrand disease screening in the izmir region. Turk J Haematol 2013;30:40–7. https://doi.org/10.4274/tjh.2011.0020 .
doi: 10.4274/tjh.2011.0020
Favaloro, EJ. Clinical utility of closure times using the platelet function analyzer (PFA)-100/200. Am J Hematol 2017;92:398–404. https://doi.org/10.1002/ajh.24620 .
doi: 10.1002/ajh.24620
Favaloro, EJ. Clinical application of the PFA-100®. Curr Opin Hematol , 2002;9:407–15. https://doi.org/10.1097/00062752-200209000-00004 .
doi: 10.1097/00062752-200209000-00004
Favaloro, EJ. Clinical utility of the PFA-100. Semin Thromb Hemost 2008;34:709–33. https://doi.org/10.1055/s-0029-1145254 .
doi: 10.1055/s-0029-1145254
Ardillon, L, Ternisien, C, Fouassier, M, Sigaud, M, Lefrançois, A, Pacault, M, et al.. Platelet function analyser (PFA-100) results and von Willebrand factor deficiency: a 16-year ’real-world’ experience. Haemophilia 2015;21:646–52. https://doi.org/10.1111/hae.12653 .
doi: 10.1111/hae.12653
Favaloro, EJ. Utility of the platelet function analyser (PFA-100/200) for exclusion or detection of von Willebrand disease: a study 22 years in the making. Thromb Res 2020;188:17–24. https://doi.org/10.1016/j.thromres.2020.01.029 .
doi: 10.1016/j.thromres.2020.01.029
Hayward, CP, Harrison, P, Cattaneo, M, Ortel, TL, Rao, AK. Platelet physiology subcommittee of the scientific and standardization committee of the international society on thrombosis and haemostasis. platelet function analyzer (PFA)-100 closure time in the evaluation of platelet disorders and platelet function. J Thromb Haemostasis 2006;4:312–9. https://doi.org/10.1111/j.1538-7836.2006.01771.x .
doi: 10.1111/j.1538-7836.2006.01771.x
Favaloro, EJ, Thom, J, Patterson, D, Just, S, Baccala, M, Dixon, T, et al.. Potential supplementary utility of combined PFA-100 and functional VWF testing for the laboratory assessment of desmopressin and factor concentrate therapy in von Willebrand disease. Blood Coagul Fibrinolysis 2009;20:475–83. https://doi.org/10.1097/mbc.0b013e32832da1ad .
doi: 10.1097/mbc.0b013e32832da1ad
Favaloro, EJ, Kershaw, G, Bukuya, M, Hertzberg, M, Koutts, J. Laboratory diagnosis of von Willebrand Disorder (VWD) and monitoring of DDAVP therapy: efficacy of the PFA-100® and VWF:CBA as combined diagnostic strategies. Haemophilia 2001;7:180–9. https://doi.org/10.1046/j.1365-2516.2001.00487.x .
doi: 10.1046/j.1365-2516.2001.00487.x
Vazquez-Santiago, M, Vilalta, N, Cuevas, B, Murillo, J, Llobet, D, Macho, R, et al.. Short closure time values in PFA-100 are related to venous thrombotic risk. Results from the RETROVE study. Thromb Res 2018;169:57–63. https://doi.org/10.1016/j.thromres.2018.07.012 .
doi: 10.1016/j.thromres.2018.07.012
Llobet, D, Vallvé, C, Tirado, I, Vilalta, N, Carrasco, M, Oliver, A, et al.. Platelet hyperaggregability and venous thrombosis risk: results from the RETROVE project. Blood Coagul Fibrinolysis 2021;32:122–31. https://doi.org/10.1097/MBC.0000000000001006 .
doi: 10.1097/MBC.0000000000001006
Koscielny, J, Ziemer, S, Radtke, H, Schmutzler, M, Pruss, A, Sinha, P, et al.. A practical concept for preoperative identification of patients with impaired primary hemostasis. Clin Appl Thromb Hemost 2004;10:195–204. https://doi.org/10.1177/107602960401000301 .
doi: 10.1177/107602960401000301
Mammen, EF, Comp, PC, Gosselin, R, Greenberg, C, Hoots, WK, Kessler, CM, et al.. PFA-100 system: a new method for assessment of platelet dysfunction. Semin Thromb Hemost 1998;24:195–202. https://doi.org/10.1055/s-2007-995840 .
doi: 10.1055/s-2007-995840
Favaloro, EJ. Towards 50 years of seminars in thrombosis and hemostasis. Semin Thromb Hemost 2022;8. in press.
Weippert-Kretschmer, M, Witte, M, Budde, U, Vigh, T, Kretschmer, V, Scharrer, I. The Thrombostat 4000. A sensitive screening test for von Willebrand’s disease. Semin Thromb Hemost 1995;21:44–51. https://doi.org/10.1055/s-0032-1313602 .
doi: 10.1055/s-0032-1313602
Kratzer, MA, Negrescu, EV, Hirai, A, Yeo, YK, Franke, P, Siess, W. The Thrombostat system. A useful method to test antiplatelet drugs and diets. Semin Thromb Hemost 1995;21:25–31. https://doi.org/10.1055/s-0032-1313599 .
doi: 10.1055/s-0032-1313599
Söhngen, D, Hattstein, E, Heyll, A, Meckenstock, G, Wienen, S, Schneider, W. Hematological parameters influencing the Thrombostat 4000. Semin Thromb Hemost 1995;21:20–4. https://doi.org/10.1055/s-0032-1313598 .
doi: 10.1055/s-0032-1313598
lshameeri, RS, Mammen, EF. Performance characteristics and clinical evaluation of an in vitro bleeding time device--Thrombostat 4000. Thromb Res 1995;79:275–87. https://doi.org/10.1016/0049-3848(95)00114-7 .
doi: 10.1016/0049-3848(95)00114-7
Högman, CF, Eriksson, L, Kristensen, J. Leukocyte-depleted platelets prepared from pooled buffy coat post-transfusion increment and “in vitro bleeding time” using the Thrombostat 4000/2. Transfus Sci 1993;14:35–9. https://doi.org/10.1016/0955-3886(93)90051-U .
doi: 10.1016/0955-3886(93)90051-U
Favaloro, EJ, Mohammed, S, Vong, R, Chapman, K, Kershaw, G, Just, S, et al.. Harmonizing platelet function analyzer testing and reporting in a large laboratory network. Int J Lab Hematol 2022. https://doi.org/10.1111/ijlh.13907 .
doi: 10.1111/ijlh.13907
Clinical and Laboratory Standards Institute (CLSI) . Defining, establishing, and verifying reference intervals in the clinical laboratory; approved guideline - third edition. CLSI document C28-A3, CLSI, 940 West Valley Road, Suite 1400, Wayne, PA 19087-1898 USA, 2008.
Lippi, G, Manzato, F, Franchini, M, Brocco, G, Florenziani, G, Guidi, G. Establishment of reference values for the PFA-100 platelet function analyzer in pediatrics. Clin Exp Med 2001;1:69–70. https://doi.org/10.1007/pl00012239 .
doi: 10.1007/pl00012239
Lippi, G, Franchini, M, Montagnana, M, Guidi, GC. Coagulation testing in pediatric patients: the young are not just miniature adults. Semin Thromb Hemost 2007;33:816–20. https://doi.org/10.1055/s-2007-1000373 .
doi: 10.1055/s-2007-1000373
Sestito, A, Sciahbasi, A, Landolfi, R, Maseri, A, Lanza, GA, Andreotti, F. A simple assay for platelet-mediated hemostasis in flowing whole blood (PFA-100): reproducibility and effects of sex and age. Cardiologia 1999;44:661–5.
Favaloro, EJ, Soltani, S, McDonald, J, Grezchnik, E, Easton, L, Favaloro, JWC. Reassessment of ABO-blood group, gender and age on laboratory parameters used to diagnose von Willebrand Disorder (VWD): potential influence on the diagnosis versus the potential association with risk of thrombosis. Am J Clin Pathol 2005;124:910–7. https://doi.org/10.1309/w76qf806ce80cl2t .
doi: 10.1309/w76qf806ce80cl2t
Favaloro, EJ, Bonar, R. An update on quality control for the PFA-100/PFA-200. Platelets 2018;29:622–7. https://doi.org/10.1080/09537104.2018.1475636 .
doi: 10.1080/09537104.2018.1475636
Golanski, J, Pluta, J, Baraniak, J, Watala, C. Limited usefulness of the PFA-100 for the monitoring of ADP receptor antagonists--in vitro experience. Clin Chem Lab Med 2004;42:25–9. https://doi.org/10.1515/CCLM.2004.006 .
doi: 10.1515/CCLM.2004.006
Stegnar, M, Bozic, M, Dolenc, MS, Anderluh, PS, Kikelj, D. Utility of PFA-100 closure time vs. optical aggregometry in assessing the efficacy of platelet membrane glycoprotein IIb/IIIa antagonists in vitro. Clin Chem Lab Med 2007;45:1542–8. https://doi.org/10.1515/CCLM.2007.318 .
doi: 10.1515/CCLM.2007.318
Wallin, O, Söderberg, J, Grankvist, K, Jonsson, PA, Hultdin, J. Preanalytical effects of pneumatic tube transport on routine haematology, coagulation parameters, platelet function and global coagulation. Clin Chem Lab Med 2008;46:1443–9. https://doi.org/10.1515/CCLM.2008.288 .
doi: 10.1515/CCLM.2008.288
Favaloro, EJ, Bonar, R. Proficiency testing/external quality assurance for the PFA-100(®). Clin Chem Lab Med 2012;50:1393–401. https://doi.org/10.1515/cclm-2012-0002 .
doi: 10.1515/cclm-2012-0002
Favaloro, EJ. Time for a conceptual shift in assessment of internal quality control for whole blood or cell-based testing systems? An evaluation using platelet function and the PFA-100 as a case example. Clin Chem Lab Med 2013;51:767–74. https://doi.org/10.1515/cclm-2012-0616 .
doi: 10.1515/cclm-2012-0616
Eller, T, Busse, J, Dittrich, M, Flieder, T, Alban, S, Knabbe, C, et al.. Dabigatran, rivaroxaban, apixaban, argatroban and fondaparinux and their effects on coagulation POC and platelet function tests. Clin Chem Lab Med 2014;52:835–44. https://doi.org/10.1515/cclm-2013-0936 .
doi: 10.1515/cclm-2013-0936
Fierro, T, Bartolini, A, Mezzasoma, AM, Guglielmini, G, Falcinelli, E, Orsini, S, et al.. Prevalence of hemostatic alterations in patients with recurrent spontaneous subconjunctival hemorrhage. Clin Chem Lab Med 2016;54:97–103. https://doi.org/10.1515/cclm-2015-0274 .
doi: 10.1515/cclm-2015-0274
Valsami, S, Kollia, M, Mougiou, V, Sokou, R, Isaakidou, E, Boutsikou, M, et al.. Evaluation of PFA-100 closure times in cord blood samples of healthy term and preterm neonates. Clin Chem Lab Med 2020;58:e113–6. https://doi.org/10.1515/cclm-2019-0948 .
doi: 10.1515/cclm-2019-0948
Rolling, CC, Tomada, J, Frölich, AM, Holst, B, Holstein, K, Voigtländer, M, et al.. Comparison of acetylsalicylic acid and clopidogrel non-responsiveness assessed by light transmittance aggregometry and PFA-100® in patients undergoing neuroendovascular procedures. Clin Chem Lab Med 2020;59:383–92. https://doi.org/10.1515/cclm-2020-0737 .
doi: 10.1515/cclm-2020-0737
Thijs, T, Nuyttens, BP, Deckmyn, H, Broos, K. Platelet physiology and antiplatelet agents. Clin Chem Lab Med 2010;(Suppl 1):S3–13. https://doi.org/10.1515/CCLM.2010.363 .
doi: 10.1515/CCLM.2010.363
Favaloro, EJ, Lippi, G, Franchini, M. Contemporary platelet function testing. Clin Chem Lab Med 2010;48:579–98. https://doi.org/10.1515/CCLM.2010.121 .
doi: 10.1515/CCLM.2010.121
Stegnar, M, Knezevic, A, Bozic-Mijovski, M. The effect of pre-analytical variables on light transmittance aggregometry in citrated platelet-rich plasma from healthy subjects. Clin Chem Lab Med 2010;48:1463–5. https://doi.org/10.1515/CCLM.2010.285 .
doi: 10.1515/CCLM.2010.285
Mani, H, Hellis, M, Lindhoff-Last, E. Platelet function testing in hirudin and BAPA anticoagulated blood. Clin Chem Lab Med 2011;49:501–7. https://doi.org/10.1515/CCLM.2011.074 .
doi: 10.1515/CCLM.2011.074
Andreasen, JB, Pistor-Riebold, TU, Knudsen, IH, Ravn, HB, Hvas, AM. Evaluation of different sized blood sampling tubes for thromboelastometry, platelet function, and platelet count. Clin Chem Lab Med 2014;52:701–6. https://doi.org/10.1515/cclm-2013-0836 .
doi: 10.1515/cclm-2013-0836
Carubbi, C, Masselli, E, Nouvenne, A, Russo, D, Galli, D, Mirandola, P, et al.. Laboratory diagnostics of inherited platelet disorders. Clin Chem Lab Med 2014;52:1091–106. https://doi.org/10.1515/cclm-2014-0131 .
doi: 10.1515/cclm-2014-0131
Meiring, M, Badenhorst, PN, Kelderman, M. Performance and utility of a cost-effective collagen-binding assay for the laboratory diagnosis of Von Willebrand disease. Clin Chem Lab Med 2007;45:1068–72.
Franchini, M, Crestani, S, Frattini, F, Sissa, C, Bonfanti, C. ABO blood group and von Willebrand factor: biological implications. Clin Chem Lab Med 2014;52:1273–6. https://doi.org/10.1515/cclm-2014-0564 .
doi: 10.1515/cclm-2014-0564